Sodium-glucose cotransporter 2 inhibitor use and outcomes in transthyretin amyloid cardiomyopathy

Transthyretin amyloid cardiomyopathy (ATTR-CM) is caused by myocardial deposition of misfolded transthyretin protein-forming amyloid fibrils which can result in symptomatic heart failure (HF).1 The only medication currently approved by the U.S. Food and Drug Administration for the treatment of ATTR-CM is tafamidis which has been shown to reduce cardiovascular-related hospitalization and all-cause mortality (ACM).1